Automated Process Control for the Development Laboratory - - BioPharm International

ADVERTISEMENT

Automated Process Control for the Development Laboratory


BioPharm International
Volume 19, Issue 3


Meg Kay
The Process Science group at a Northern California biopharmaceutical company recently changed its methods of data management and process control from manual to automated. The company's Lab Director said that, thanks to the automation now in place, "We have realized a 30% savings in time, resulting in substantial development cost reductions."

The actual installation of the automation system throughout their bacterial fermentation lab took a single day. Luckily, the installation could be done between experiments, but if experiments had been running, the reactors could have stayed under manual control for that time. At the end of that day, the reactors were up and running again, under the eye of a networked, automated data management and control system.


Jova Solutions
The staff attended two days of training on-site, one day geared to researchers and the other to technicians. Over time, various customizations and new instruments were added, nearly all without shutting down the system or interrupting running experiments.

The bacterial fermentation lab did not need to have any of its instrumentation replaced in order to install the new automated system. All the existing instruments were brought together under one unified interface. All sources of data were managed together, all available for display, calculations, and control. New instruments were added later, and they were integrated with the rest.

We want to tell the story of this change because many labs are contemplating automating, but are fearful of disruption. This case history shows that it can be quick, nearly painless, and has huge advantages.

REGULATORY INCENTIVE

Biopharmaceutical companies struggle to comply with FDA regulations, good laboratory practices (GLP) current good manufacturing practices (cGMP), and process automation technology (PAT) standards during process development, scaleup, and production. Manual methods make this difficult, because changes can't be recorded and tracked, procedures can't be repeated exactly, and systems are less secure. The system security and tracking commonly found in FDA 21 CFR Part 11-compliant manufacturing facilities would be great in process development, but the high cost and inflexibility of the systems usually selected for manufacturing makes them impractical.


Figure 1. Automated process control and data management allows easy expansion.
However, a good software solution enables FDA-compliant systems for labs and pilot plants, with full security and tracking features, without sacrificing the flexibility and openness required during process development. The tracking is transparent to users of the system, and the security can be configured by each facility to be as free or as rigorous as required. When new instrumentation is purchased, it can be integrated into the same interface as illustrated in Figure 1.

The most noticeable benefit of incorporating a comprehensive system is that laboratory scientists are freed from the mundane manual methods of data collection, analysis, and control, and can focus on essential research and development. To make things even easier, having a unified interface for all sources of data means the people in the labs don't have to learn all the different systems. A Senior Process Development Scientist at a large West Coast biotech company pointed out the advantage of this, "Having a common data platform saves time and money in training and in the overhead of integrating different data sources and training on different systems."

As pressure on biopharmaceutical companies to accelerate the commercialization of life-saving biotherapeutics and comply with government regulation increases, incorporating advanced process control and data management is essential. Biopharmaceutical companies are facing major challenges and are; "...compelled to incorporate tools that can improve their productivity and reduce R&D expenditures," according to analyst Raghavendra Chitta of Frost & Sullivan in a July 2005 report.

One senior process development scientist at a large West Coast biotech company made the benefits of automation clear when he said that this automation software, "...gives us profit maximization... We get products to market faster... if we're one month faster to market, that is significant added value —as in more revenue."


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here